Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Advanced Hepatocellular CarcinomaAnti-PD1/PDL1 AntibodyBevacizumab
Interventions
PROCEDURE

Locoregional therapy

"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."

DRUG

Bevacizumab

15mg/kg or 7.5mg/kg intravenously every 3 weeks

DRUG

Atezolizumab

1200mg intravenously every 3 weeks

DRUG

Tislelizumab

200mg intravenously every 3 weeks

DRUG

Toripalimab

220mg intravenously every 3 weeks

DRUG

Sintilimab

200mg intravenously every 3 weeks

DRUG

Camrelizumab

200mg intravenously every 3 weeks

Trial Locations (1)

100853

RECRUITING

Chinese PLA hospital, Beijing

All Listed Sponsors
lead

Sun Yat-sen University

OTHER